China
Africa
Explore chapters and articles related to this topic
IOMP’s Global Perspectives for Medical Physics during the COVID-19 Pandemic
Published in Kwan Hoong Ng, Magdalena S. Stoeva, Medical Physics During the COVID-19 Pandemic, 2021
Magdalena Stoeva, Kwan Hoong Ng, John Damilakis, Madan M. Rehani
Medical physics departments should have guidelines in place to ensure the safety of patients and staff. Radioisotope therapy patients who are “at risk” should be seen and treated in a separate room. Dosimeters, radiation protection garments (patient shielding, aprons, etc.), image viewing stations, and computer peripheries need to be disinfected regularly. IOMP national member organizations have worked to ensure the safety of patients and personnel during the pandemic [14].
Radiation protection in medicine
Published in Alan Martin, Sam Harbison, Karen Beach, Peter Cole, An Introduction to Radiation Protection, 2018
Alan Martin, Sam Harbison, Karen Beach, Peter Cole
Also, in radioisotope therapy, cancers can be treated using unsealed radioactive materials. For example, many gigabecquerels of iodine-131 (I-131) can be administered orally to patients in radiotherapy for thyroid cancer. The use of unsealed radioisotopes in medical diagnosis and therapy is dealt with in Section 16.5.2.
Management of bone pain
Published in Nigel Sykes, Michael I Bennett, Chun-Su Yuan, Clinical Pain Management, 2008
Radioisotope therapy is an alternative to wide field irradiation. It involves the intravenous administration of a radioisotope which will be selectively taken up at sites of bone metastases. Isotopes in common use are shown in Table 20.4. The ideal isotope will deliver radiation through decay to predominantly beta particle irradiation of limited range, 2–4 mm, to deposit its energy within the bone metastasis in which it is localized. A small component of low energy gamma irradiation is also of value as it can be detected by a gamma camera to give pictures analogous to a diagnostic bone scan showing the distribution of the isotope uptake.
Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
Published in Journal of Medical Economics, 2020
Huamao M. Lin, Xiaoyun Pan, Peijie Hou, Hui Huang, Yanyu Wu, Kaili Ren, Mohammad Jahanzeb
Among the non-inpatient procedure costs, radiation therapy costs were 3.5-times higher in patients with BM compared to no BM. These therapies include radium/radioisotope therapy, radiation treatment aids, stereotactic radiosurgery (multisource), and stereotactic body radiation therapy. In addition, the cost of radiographic procedures was 2.2-times higher in the patients with BM compared to no BM. The costs for medication procedures, including chemotherapy treatments such as pemetrexed and anti-programmed death-ligand 1, accounted for a similar percentage of total non-inpatient procedure costs for patients with and without BM.
Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study
Published in Journal of Dermatological Treatment, 2022
Cesidio Cipriani, Maria Desantis, Gerhard Dahlhoff, Shannon D. Brown, Thomas Wendler, Mar Olmeda, Gunilla Pietsch, Bernadette Eberlein
This epidermal radioisotope therapy using rhenium-188 is commercially known as Rhenium-SCT®. The medical working principle of the Rhenium-SCT®, or epidermal radioisotope therapy, is based on the local direct cell-killing effect of the beta-radiation, which triggers both the local death of cells and local reactions of the immune system of the body to repair itself. This radioisotope therapy to treat NMSC with non-sealed rhenium-188 offers a personalized solution for NMSC patients and is already available in specialized centers in Italy, South Africa, Australia, and Germany.